The global nicotine gum market is currently witnessing a healthy growth. Nicotine gum is an over the counter (OTC) smoking cessation product. It aims to assist individuals suffering from tobacco dependence in minimizing their consumption of cigarettes and eventually quit smoking. Nicotine is released when the gum is chewed and is absorbed into the bloodstream through the lining of the mouth. This aids in gradually curbing nicotine cravings and reducing the withdrawal symptoms and urge to smoke. It is commonly available in three variants: 2mg, 4mg and 6mg based on the nicotine content and is used by the individuals based on the number of cigarettes consumed by them on a daily basis.
The rising instances of lung cancer and other respiratory disorders is one of the key factors driving the growth of the market. Smoking is known to cause various chronic diseases, such as coronary heart disease (CHD), stroke, oropharyngeal cancer, esophageal cancer, tuberculosis, rheumatoid arthritis and various immunity-related ailments. The rising awareness regarding these ailments, along with the increasing health consciousness, is contributing to the market growth. Additionally, widespread adoption of smoking cessation therapies is acting as another growth-inducing factor. Various government and non-government organizations (NGOs) across both the developed and emerging nations are promoting the usage of smoking cessation products, such as nicotine gums, to assist individuals, especially the youth, with tobacco addiction. Other factors, including various product innovations such as the development of nicotine lozenges, rapid urbanization and extensive research and development activities, are projected to drive the market further. Looking forward, IMARC Group expects the market to grow at a CAGR of around 4% during 2020-2025.
Breakup by Type:
Breakup by Application:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined with some of the key players being British American Tobacco, Cambrex Corporation, GlaxoSmithKline, ITC Limited, Johnson & Johnson Services, Novartis, Perrigo, Pfizer, Takeda Pharmaceutical Company, etc.
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at